AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3292811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg single dose)
Number of subjects: 16
Study 3292811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day for two weeks)
Number of subjects: 16
Study 3292811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day for long-term use, average 13.9 months)
Number of subjects: 16
Study 31515972 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP1M)
Number of subjects: 0
Study 31515972 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-every-3-months paliperidone palmitate (PP3M)
Number of subjects: 0
Study 31515972 — intervention group
Group type: EXPERIMENTAL
Intervention: PP1M/PP3M
Number of subjects: 0
Study 31434507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg once daily)
Number of subjects: 3796
Study 31434507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3796
Study 28288972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60
Study 28288972 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic disease-modifying antirheumatic drugs
Number of subjects: 60
Study 28288972 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor α
Number of subjects: 60
Study 28288972 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 25733653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis at a dose of 10^9 colony-forming units/d
Number of subjects: 727
Study 25733653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 24303412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexamethasone (B+D)
Number of subjects: 60
Study 24303412 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (B)
Number of subjects: 60
Study 21595816 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based education
Number of subjects: 41
Study 21595816 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 41
Study 19838972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestrectomy
Number of subjects: 100
Study 19838972 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 100
Study 16336993 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group education
Number of subjects: 354
Study 16336993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low t-score feedback
Number of subjects: 354
Study 16336993 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal physical activity
Number of subjects: 354
Study 16336993 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 354
Study 16336993 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis information leaflet
Number of subjects: 354
Study 16336993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 354
Study 14706581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl suture (VS)
Number of subjects: 48
Study 14706581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesive (CTA)
Number of subjects: 48
Study 14706581 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tape (ST)
Number of subjects: 48
Study 11708240 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS program (FGCBT)
Number of subjects: 71
Study 11708240 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study 11708240 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures by children and mothers
Number of subjects: 71
Study 11708240 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction reported by parents and children
Number of subjects: 71
Study 9219984 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium RPDs
Number of subjects: 20
Study 9219984 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium RPDs
Number of subjects: 20
Study 8511727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 750 micrograms twice daily
Number of subjects: 105
Study 8511727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 1500 micrograms twice daily
Number of subjects: 105
Study 8511727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 40 mg per day
Number of subjects: 105
Study 8511727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8511727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP)
Number of subjects: 105
Study 3493852 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg X kg‐1)
Number of subjects: 90
Study 3493852 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4 mg X kg‐1)
Number of subjects: 90
Study 29219638 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 308
Study 29219638 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 308
Study 29219638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study 26952220 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 34
Study 26952220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 34
Study 26952220 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 34
Study 24253785 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiva implant with low viscosity PMMA
Number of subjects: 47
Study 24253785 — intervention group
Group type: COMPARATOR
Intervention: Balloon kyphoplasty (BK) with high viscosity PMMA
Number of subjects: 47
Study 22531562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control (TGC) implemented in intervention ICUs
Number of subjects: 1321
Study 20831627 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI)
Number of subjects: 99
Study 18587715 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive treatment including ACE inhibitors, AT1 blockers, statins, dietary counseling, and smoking cessation programs.
Number of subjects: 148
Study 18587715 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive treatment including steroids or steroids plus cyclophosphamide/azathioprine, in addition to supportive treatment.
Number of subjects: 148
Study 15752376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg
Number of subjects: 18
Study 15752376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12187613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chromium picolinate (Cr-pic) supplementation (924 micrograms Cr/d)
Number of subjects: 17
Study 12187613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training (RT)
Number of subjects: 17
Study 12187613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-Cr, < 0.2 microgram Cr/d)
Number of subjects: 17
Study 10963286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0, 1, and 2 months
Number of subjects: 956
Study 10963286 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0 and 1 months
Number of subjects: 956
Study 9202588 — intervention group
Group type: EXPERIMENTAL
Intervention: HASTE MR
Number of subjects: 55
Study 9202588 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 55
Study 9202588 — intervention group
Group type: COMPARATOR
Intervention: IVU
Number of subjects: 55
Study 1300782 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy in ER+PR+ tumor patients
Number of subjects: 271
Study 1300782 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 271
Study 1300782 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapy
Number of subjects: 271
Study 1300782 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-positivity
Number of subjects: 271
Study 3895545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride tablets (FLUDENT) for daily sucking twice a day plus a placebo dentifrice free of fluoride
Number of subjects: 376
Study 3895545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.025% F (ACTA)
Number of subjects: 376
Study 3895545 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo dentifrice plus fluoride varnish (Duraphat) twice a year
Number of subjects: 376
Study 3895545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.025% F (ACTA) plus fluoride varnish (Duraphat) twice a year
Number of subjects: 376
Study 28694009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual red imaging (DRI)
Number of subjects: 79
Study 28694009 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 79
Study 28059434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 10
Study 28059434 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg)
Number of subjects: 10
Study 28059434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Normal Saline)
Number of subjects: 10
Study 24217129 — intervention group
Group type: EXPERIMENTAL
Intervention: VRE-DCS (100 mg D-cycloserine administered 90 min before each weekly VRE session)
Number of subjects: 25
Study 24217129 — intervention group
Group type: COMPARATOR
Intervention: VRE-placebo (placebo administered 90 min before each weekly VRE session)
Number of subjects: 25
Study 22878793 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm priming solution at 36 °C
Number of subjects: 40
Study 22878793 — intervention group
Group type: COMPARATOR
Intervention: Cold priming solution at 20 °C
Number of subjects: 40
Study 20484012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of octreotide (a somatostatin analog)
Number of subjects: 16
Study 20484012 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control condition)
Number of subjects: 16
Study 18712481 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Charge of Your Life program (treatment condition)
Number of subjects: 19200
Study 18712481 — intervention group
Group type: COMPARATOR
Intervention: Control condition (schools offering drug prevention programming)
Number of subjects: 19200
Study 15905806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 200 mg/d for 11 days
Number of subjects: 10
Study 15905806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12857704 — intervention group
Group type: EXPERIMENTAL
Intervention: Projective bone area (BA) size at the PA lumbar spine
Number of subjects: 1436
Study 12857704 — intervention group
Group type: EXPERIMENTAL
Intervention: Projective bone area (BA) size at the lateral lumbar spine
Number of subjects: 1436
Study 12857704 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection rates of osteoporosis by aBMD
Number of subjects: 1436
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramodality Prior Exposure (IPE) - neutral, non-stressful stimulation in the same modality
Number of subjects: 0
Study 10858569 — intervention group
Group type: COMPARATOR
Intervention: Cross-modality Prior Exposure (CPE) - neutral stimuli in a different modality
Number of subjects: 0
Study 10858569 — intervention group
Group type: COMPARATOR
Intervention: Stress Only (SO) - a rest period
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trait anxious subjects
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait anxious subjects
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimuli
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective stimuli
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mediational conditions
Number of subjects: 0
Study 10858569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational conditions
Number of subjects: 0
Study 8891716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session condom promotion intervention
Number of subjects: 198
Study 8891716 — intervention group
Group type: COMPARATOR
Intervention: Control (stress management) intervention
Number of subjects: 198
Study 31217488 — intervention group
Group type: EXPERIMENTAL
Intervention: Runs test
Number of subjects: 73
Study 31217488 — intervention group
Group type: EXPERIMENTAL
Intervention: Within test response bias
Number of subjects: 73
Study 31217488 — intervention group
Group type: COMPARATOR
Intervention: Forced Choice Test (FCT)
Number of subjects: 73
Study 29351792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention for people with severe mental ill health
Number of subjects: 526
Study 27488569 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF measured by left ventriculography
Number of subjects: 445
Study 27488569 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 40%
Number of subjects: 445
Study 27488569 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF measured by echocardiography
Number of subjects: 445
Study 27488569 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF measured within 24 hours
Number of subjects: 445
Study 27488569 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF measured not within 24 hours
Number of subjects: 445
Study 25132340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA injections
Number of subjects: 0
Study 25132340 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (no intervention)
Number of subjects: 0
Study 22273588 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss study intervention at community colleges
Number of subjects: 1004
Study 22273588 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss study intervention
Number of subjects: 1004
Study 18682717 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin
Number of subjects: 45
Study 16260029 — intervention group
Group type: EXPERIMENTAL
Intervention: Irofulven at 24 mg/m2 every 14 days
Number of subjects: 74
Study 16260029 — intervention group
Group type: EXPERIMENTAL
Intervention: Irofulven at 0.55 mg/kg every 14 days
Number of subjects: 74
Study 12414079 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR)
Number of subjects: 34
Study 12414079 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 34
Study 11063636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (1.5 g/m(2)/day for 5 days every 3 weeks for eight courses with mesna uroprotection)
Number of subjects: 194
Study 11063636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide-cisplatin (ifosfamide with cisplatin 20 mg/m(2)/day for 5 days)
Number of subjects: 194
Study 11063636 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide alone
Number of subjects: 194
Study 11063636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide-cisplatin
Number of subjects: 194
Study 8885752 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 59
Study 8885752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution plus physiologic glucose
Number of subjects: 59
Study 8885752 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 59
Study 1573338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600mg/day
Number of subjects: 61
Study 1573338 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen 0.5mg t.i.d.
Number of subjects: 61
Study 3891347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone (600 to 900 mg daily)
Number of subjects: 12
Study 3891347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3891347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone (doses exceeding 450 mg day‐1)
Number of subjects: 12
Study 3891347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone
Number of subjects: 12
Study 30282662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body therapy (MBT) intervention; duration: two days
Number of subjects: 46
Study 26566681 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 74
Study 26566681 — intervention group
Group type: COMPARATOR
Intervention: Methadone syrup
Number of subjects: 74
Study 24814767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh (pore size 3-4 mm)
Number of subjects: 134
Study 24814767 — intervention group
Group type: COMPARATOR
Intervention: Optilene LP mesh (pore size 1 mm)
Number of subjects: 134
Study 24814767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 22245620 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 60
Study 22245620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22245620 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 20447037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week catheterization
Number of subjects: 56
Study 20447037 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week catheterization
Number of subjects: 56
Study 20447037 — intervention group
Group type: COMPARATOR
Intervention: Control (1-week catheterization)
Number of subjects: 56
Study 19098693 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-penetrating needle
Number of subjects: 114
Study 19098693 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating needle
Number of subjects: 114
Study 15986086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) administered using a mat 1.8 x 0.6 m in size, 30 min per session, twice a day for 3 weeks
Number of subjects: 34
Study 15986086 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo group)
Number of subjects: 34
Study 12839630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 412
Study 12839630 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 hours
Number of subjects: 412
Study 10952480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylene blue (100 mg)
Number of subjects: 7
Study 10952480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylene blue (100 mg)
Number of subjects: 7
Study 10952480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal methylene blue (in rats)
Number of subjects: 7
Study 10952480 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue with mesna (100 mg)
Number of subjects: 7
Study 9015418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor), 12 weeks treatment
Number of subjects: 34
Study 9015418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9015418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 34
Study 1801157 — intervention group
Group type: EXPERIMENTAL
Intervention: Amocarzine (CGP 6140) - a new oral macrofilaricidal compound, administered in three repeat dose regimens.
Number of subjects: 24
Study 1801157 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group, consisting of 6 patients.
Number of subjects: 24
Study 1801157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography using an ophthalmologic real time linear scanner.
Number of subjects: 24
Study 1801157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodulectomy performed on six nodules around day 10 for initial control purposes.
Number of subjects: 24
Study 6345161 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 49781
Study 30829982 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-5-HIIT
Number of subjects: 34
Study 30829982 — intervention group
Group type: COMPARATOR
Intervention: 20-10-HIIT
Number of subjects: 34
Study 29357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (eccentric wrist flexion, 3 times/week for 4 weeks)
Number of subjects: 16
Study 27017071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 12 weeks
Number of subjects: 1075
Study 27017071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 24998117 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow desflurane anesthesia (Group HF)
Number of subjects: 40
Study 24998117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow desflurane anesthesia (Group LF)
Number of subjects: 40
Study 22004181 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Heart Failure DVD and booklet
Number of subjects: 480
Study 22004181 — intervention group
Group type: COMPARATOR
Intervention: Basic written materials only
Number of subjects: 480
Study 20179530 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical T staging (T1, T2, T3, T4)
Number of subjects: 1964
Study 20179530 — intervention group
Group type: EXPERIMENTAL
Intervention: UICC/AJCC N staging (N0, N1)
Number of subjects: 1964
Study 20179530 — intervention group
Group type: EXPERIMENTAL
Intervention: JCGC n staging (n0, n1, n2, n3)
Number of subjects: 1964
Study 20179530 — intervention group
Group type: EXPERIMENTAL
Intervention: JCGC n staging within UICC/AJCC N1 category
Number of subjects: 1964
Study 19005869 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 30
Study 19005869 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensorial stimulation (MSS)
Number of subjects: 30
Study 19005869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15629419 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 0
Study 15629419 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 15629419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham acupuncture with Streitberger needles)
Number of subjects: 0
Study 15629419 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Acupuncture Sensation Scale (SASS)
Number of subjects: 0